Share Price and Basic Stock Data
Last Updated: February 7, 2026, 7:32 pm
| PEG Ratio | -1.86 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kopran Ltd operates in the pharmaceuticals industry, emphasizing the development and manufacturing of a range of pharmaceutical products. The company’s stock is currently priced at ₹123, with a market capitalization of ₹595 Cr. Over the past few quarters, Kopran has demonstrated fluctuating sales performance. The revenue from operations recorded ₹551 Cr for the fiscal year ending March 2023, which rose to ₹615 Cr for March 2024, indicating a growth trajectory. However, the trailing twelve months (TTM) revenue stood at ₹592 Cr, reflecting a slight decline from the FY 2024 figure. Quarterly sales figures reveal a peak of ₹186.08 Cr in March 2024, followed by a drop to ₹139.44 Cr in June 2024, illustrating volatility in revenue generation. The company’s operating profit margin (OPM) has been negative at -4.48% as of September 2025, suggesting challenges in cost management and pricing strategy. The significant variability in sales and OPM necessitates a closer examination of the company’s operational efficiencies and market positioning.
Profitability and Efficiency Metrics
Kopran Ltd’s profitability metrics reveal a complex picture. The company reported a net profit of ₹18 Cr for the fiscal year ending March 2025, down from ₹39 Cr in March 2024. The earnings per share (EPS) also reflected this downturn, standing at ₹7.99 for March 2025, compared to ₹10.57 the previous year. Operating profit margins have fluctuated, with a notable decline to -4.48% in September 2025 after reaching as high as 14.96% in September 2023. The interest coverage ratio (ICR) stood at a healthy 8.23x, indicating that the company can comfortably meet its interest obligations. However, the return on equity (ROE) is at 7.64%, which is below the industry average, suggesting that shareholders may not be receiving optimal returns on their investments. The cash conversion cycle (CCC) of 170 days reflects inefficiencies in managing working capital, particularly in receivables and inventory management, which could affect liquidity and operational flexibility.
Balance Sheet Strength and Financial Ratios
Kopran Ltd’s balance sheet reveals both strengths and areas of concern. Total assets amounted to ₹844 Cr as of March 2025, with reserves reported at ₹470 Cr. The company’s total borrowings stood at ₹148 Cr, indicating a manageable debt level relative to its equity capital of ₹48 Cr. The debt-to-equity ratio is relatively low at 0.28, showcasing prudent financial leverage. However, the current ratio of 1.76 suggests that the company has adequate liquidity to cover its short-term obligations, though it is lower than the previous year’s 2.08. The price-to-book value (P/BV) ratio stood at 1.63x, indicating that the stock is trading at a reasonable valuation compared to its book value. The return on capital employed (ROCE) has declined to 10% in March 2025, down from 14% in the previous year, which raises questions about the efficiency of capital utilization in generating profits.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Kopran Ltd reflects a stable yet cautious investor sentiment. As of September 2025, promoters hold 44.43% of the company, indicating strong insider confidence. However, foreign institutional investors (FIIs) hold a mere 0.60%, while domestic institutional investors (DIIs) hold none, suggesting limited institutional interest. The public holds 54.99% of the shares, with the number of shareholders increasing to 62,222, which indicates growing retail interest. Despite this, the low participation from institutional investors could be a red flag for potential investors, as it may imply skepticism about the company’s growth prospects. The dividend payout ratio has varied, with a reported 38% for March 2025, reflecting a commitment to returning capital to shareholders despite recent profitability challenges. This pattern of shareholding might influence future capital raising and strategic decisions.
Outlook, Risks, and Final Insight
Kopran Ltd faces a mixed outlook going forward. On one hand, the company has demonstrated resilience in increasing its revenue base, growing from ₹551 Cr in FY 2023 to ₹615 Cr in FY 2024. However, the declining profitability metrics, specifically the net profit and OPM, raise concerns about sustainability. Risks include high operational costs, as indicated by a negative OPM, and potential challenges in managing working capital effectively. Additionally, the low institutional interest could hinder future funding opportunities. Conversely, the company’s manageable debt levels and strong promoter holding suggest that it has a solid foundation to address these challenges. In a scenario where Kopran can streamline its operations and improve its margins, it may enhance profitability and investor confidence. Conversely, continued struggles with cost management and revenue volatility may lead to further declines in shareholder value. Thus, the company’s ability to adapt and respond to these dynamics will be crucial for its future performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 128 Cr. | 102 | 185/84.3 | 28.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,529 Cr. | 324 | 479/192 | 73.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.0 Cr. | 53.9 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,604.55 Cr | 1,093.01 | 42.93 | 202.24 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 158.00 | 148.88 | 117.00 | 152.59 | 158.92 | 186.08 | 139.44 | 151.56 | 166.24 | 172.36 | 135.22 | 117.91 | 194.28 |
| Expenses | 145.68 | 136.72 | 110.69 | 129.76 | 135.34 | 164.39 | 121.28 | 136.83 | 146.39 | 155.27 | 121.09 | 123.19 | 176.52 |
| Operating Profit | 12.32 | 12.16 | 6.31 | 22.83 | 23.58 | 21.69 | 18.16 | 14.73 | 19.85 | 17.09 | 14.13 | -5.28 | 17.76 |
| OPM % | 7.80% | 8.17% | 5.39% | 14.96% | 14.84% | 11.66% | 13.02% | 9.72% | 11.94% | 9.92% | 10.45% | -4.48% | 9.14% |
| Other Income | 2.22 | 3.78 | 2.39 | 0.13 | 2.43 | 9.67 | 2.63 | 1.00 | 0.17 | 3.26 | 2.56 | 0.03 | 0.07 |
| Interest | 2.24 | 1.78 | 1.83 | 1.94 | 2.24 | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 | 2.09 | 2.67 |
| Depreciation | 3.16 | 3.24 | 3.26 | 2.77 | 3.27 | 3.59 | 3.87 | 3.85 | 4.00 | 3.87 | 4.26 | 4.28 | 4.42 |
| Profit before tax | 9.14 | 10.92 | 3.61 | 18.25 | 20.50 | 25.18 | 14.74 | 9.65 | 13.86 | 13.71 | 9.89 | -11.62 | 10.74 |
| Tax % | 23.96% | 26.37% | 22.99% | 24.55% | 23.02% | 26.01% | 24.69% | 23.42% | 24.96% | 29.39% | 24.67% | -14.63% | 13.04% |
| Net Profit | 6.95 | 8.04 | 2.77 | 13.77 | 15.79 | 18.62 | 11.10 | 7.38 | 10.40 | 9.68 | 7.45 | -9.92 | 9.34 |
| EPS in Rs | 1.44 | 1.67 | 0.57 | 2.86 | 3.28 | 3.86 | 2.30 | 1.53 | 2.16 | 2.01 | 1.54 | -2.06 | 1.94 |
Last Updated: February 5, 2026, 6:16 am
Below is a detailed analysis of the quarterly data for Kopran Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 194.28 Cr.. The value appears strong and on an upward trend. It has increased from 117.91 Cr. (Sep 2025) to 194.28 Cr., marking an increase of 76.37 Cr..
- For Expenses, as of Dec 2025, the value is 176.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 123.19 Cr. (Sep 2025) to 176.52 Cr., marking an increase of 53.33 Cr..
- For Operating Profit, as of Dec 2025, the value is 17.76 Cr.. The value appears strong and on an upward trend. It has increased from -5.28 Cr. (Sep 2025) to 17.76 Cr., marking an increase of 23.04 Cr..
- For OPM %, as of Dec 2025, the value is 9.14%. The value appears strong and on an upward trend. It has increased from -4.48% (Sep 2025) to 9.14%, marking an increase of 13.62%.
- For Other Income, as of Dec 2025, the value is 0.07 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Sep 2025) to 0.07 Cr., marking an increase of 0.04 Cr..
- For Interest, as of Dec 2025, the value is 2.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.09 Cr. (Sep 2025) to 2.67 Cr., marking an increase of 0.58 Cr..
- For Depreciation, as of Dec 2025, the value is 4.42 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.28 Cr. (Sep 2025) to 4.42 Cr., marking an increase of 0.14 Cr..
- For Profit before tax, as of Dec 2025, the value is 10.74 Cr.. The value appears strong and on an upward trend. It has increased from -11.62 Cr. (Sep 2025) to 10.74 Cr., marking an increase of 22.36 Cr..
- For Tax %, as of Dec 2025, the value is 13.04%. The value appears to be increasing, which may not be favorable. It has increased from -14.63% (Sep 2025) to 13.04%, marking an increase of 27.67%.
- For Net Profit, as of Dec 2025, the value is 9.34 Cr.. The value appears strong and on an upward trend. It has increased from -9.92 Cr. (Sep 2025) to 9.34 Cr., marking an increase of 19.26 Cr..
- For EPS in Rs, as of Dec 2025, the value is 1.94. The value appears strong and on an upward trend. It has increased from -2.06 (Sep 2025) to 1.94, marking an increase of 4.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:05 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 303 | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 478 | 551 | 615 | 630 | 592 |
| Expenses | 260 | 294 | 266 | 274 | 283 | 312 | 313 | 410 | 390 | 499 | 540 | 557 | 546 |
| Operating Profit | 43 | 31 | 30 | 36 | 31 | 46 | 47 | 82 | 87 | 52 | 74 | 73 | 46 |
| OPM % | 14% | 10% | 10% | 12% | 10% | 13% | 13% | 17% | 18% | 9% | 12% | 12% | 8% |
| Other Income | 2 | -48 | 1 | 11 | 9 | 3 | -0 | 18 | 11 | 3 | 15 | 4 | 6 |
| Interest | 14 | 13 | 13 | 14 | 9 | 9 | 9 | 6 | 5 | 6 | 9 | 9 | 10 |
| Depreciation | 13 | 10 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 13 | 16 | 16 |
| Profit before tax | 17 | -39 | 11 | 25 | 23 | 32 | 28 | 83 | 82 | 36 | 68 | 52 | 26 |
| Tax % | 0% | 0% | 0% | 20% | 10% | 24% | 26% | 26% | 25% | 24% | 25% | 26% | |
| Net Profit | 17 | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 61 | 27 | 51 | 39 | 18 |
| EPS in Rs | 4.40 | -9.52 | 2.48 | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 12.66 | 5.65 | 10.57 | 7.99 | 3.65 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 21% | 24% | 53% | 28% | 38% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -329.41% | 128.21% | 81.82% | 0.00% | 20.00% | -12.50% | 195.24% | -1.61% | -55.74% | 88.89% | -23.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | 457.62% | -46.39% | -81.82% | 20.00% | -32.50% | 207.74% | -196.85% | -54.12% | 144.63% | -112.42% |
Kopran Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | -14% |
| TTM: | -41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | -2% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 12% |
| 3 Years: | 8% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 9:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:32 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 41 | 43 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 | 48 | 48 |
| Reserves | 67 | 49 | 57 | 81 | 101 | 125 | 146 | 202 | 378 | 391 | 443 | 470 | 453 |
| Borrowings | 137 | 86 | 80 | 95 | 89 | 97 | 88 | 66 | 75 | 75 | 99 | 148 | 157 |
| Other Liabilities | 56 | 99 | 84 | 78 | 82 | 85 | 92 | 128 | 110 | 135 | 153 | 178 | 155 |
| Total Liabilities | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 813 |
| Fixed Assets | 105 | 102 | 101 | 104 | 104 | 113 | 111 | 112 | 151 | 165 | 182 | 208 | 235 |
| CWIP | 20 | 1 | 3 | 6 | 10 | 24 | 30 | 43 | 36 | 70 | 97 | 113 | 114 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 174 | 172 | 160 | 187 | 201 | 214 | 229 | 284 | 425 | 415 | 465 | 522 | 465 |
| Total Assets | 299 | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 813 |
Below is a detailed analysis of the balance sheet data for Kopran Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 48.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 48.00 Cr..
- For Reserves, as of Sep 2025, the value is 453.00 Cr.. The value appears to be declining and may need further review. It has decreased from 470.00 Cr. (Mar 2025) to 453.00 Cr., marking a decrease of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 148.00 Cr. (Mar 2025) to 157.00 Cr., marking an increase of 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 155.00 Cr.. The value appears to be improving (decreasing). It has decreased from 178.00 Cr. (Mar 2025) to 155.00 Cr., marking a decrease of 23.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 813.00 Cr.. The value appears to be improving (decreasing). It has decreased from 844.00 Cr. (Mar 2025) to 813.00 Cr., marking a decrease of 31.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 235.00 Cr.. The value appears strong and on an upward trend. It has increased from 208.00 Cr. (Mar 2025) to 235.00 Cr., marking an increase of 27.00 Cr..
- For CWIP, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 113.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 465.00 Cr.. The value appears to be declining and may need further review. It has decreased from 522.00 Cr. (Mar 2025) to 465.00 Cr., marking a decrease of 57.00 Cr..
- For Total Assets, as of Sep 2025, the value is 813.00 Cr.. The value appears to be declining and may need further review. It has decreased from 844.00 Cr. (Mar 2025) to 813.00 Cr., marking a decrease of 31.00 Cr..
Notably, the Reserves (453.00 Cr.) exceed the Borrowings (157.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -94.00 | -55.00 | -50.00 | -59.00 | -58.00 | -51.00 | -41.00 | 16.00 | 12.00 | -23.00 | -25.00 | -75.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 91 | 70 | 86 | 75 | 88 | 94 | 89 | 97 | 108 | 126 | 125 |
| Inventory Days | 103 | 78 | 119 | 122 | 138 | 129 | 154 | 121 | 202 | 133 | 126 | 153 |
| Days Payable | 69 | 119 | 115 | 95 | 118 | 90 | 95 | 104 | 84 | 89 | 103 | 108 |
| Cash Conversion Cycle | 101 | 50 | 74 | 113 | 96 | 127 | 153 | 106 | 215 | 152 | 149 | 170 |
| Working Capital Days | 45 | 9 | 34 | 43 | 60 | 70 | 79 | 81 | 158 | 139 | 131 | 113 |
| ROCE % | 14% | 14% | 14% | 19% | 14% | 16% | 14% | 30% | 21% | 8% | 14% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Healthcare Fund | 101,067 | 1.41 | 2.28 | 101,067 | 2025-04-22 17:25:28 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 251 | 0.07 | 0.01 | 251 | 2025-04-22 17:25:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 7.99 | 10.57 | 5.65 | 13.77 | 14.24 |
| Diluted EPS (Rs.) | 7.99 | 10.57 | 5.65 | 13.77 | 14.24 |
| Cash EPS (Rs.) | 11.21 | 13.24 | 8.29 | 14.96 | 16.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 107.35 | 101.90 | 91.11 | 88.40 | 56.65 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 107.35 | 101.90 | 91.11 | 88.40 | 56.65 |
| Revenue From Operations / Share (Rs.) | 130.39 | 127.48 | 114.29 | 99.05 | 113.71 |
| PBDIT / Share (Rs.) | 15.92 | 18.47 | 11.38 | 20.33 | 23.07 |
| PBIT / Share (Rs.) | 12.69 | 15.79 | 8.74 | 18.02 | 20.71 |
| PBT / Share (Rs.) | 10.76 | 14.01 | 7.48 | 16.96 | 19.27 |
| Net Profit / Share (Rs.) | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 |
| NP After MI And SOA / Share (Rs.) | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 |
| PBDIT Margin (%) | 12.21 | 14.48 | 9.95 | 20.52 | 20.28 |
| PBIT Margin (%) | 9.73 | 12.38 | 7.64 | 18.19 | 18.21 |
| PBT Margin (%) | 8.25 | 10.99 | 6.54 | 17.12 | 16.94 |
| Net Profit Margin (%) | 6.12 | 8.29 | 4.94 | 12.78 | 12.52 |
| NP After MI And SOA Margin (%) | 6.12 | 8.29 | 4.94 | 12.78 | 12.52 |
| Return on Networth / Equity (%) | 7.43 | 10.37 | 6.19 | 14.32 | 25.14 |
| Return on Capital Employeed (%) | 11.04 | 14.51 | 8.91 | 18.91 | 32.14 |
| Return On Assets (%) | 4.56 | 6.85 | 4.19 | 9.99 | 14.02 |
| Long Term Debt / Equity (X) | 0.03 | 0.03 | 0.04 | 0.04 | 0.08 |
| Total Debt / Equity (X) | 0.28 | 0.20 | 0.17 | 0.17 | 0.26 |
| Asset Turnover Ratio (%) | 0.79 | 0.88 | 0.87 | 0.45 | 0.64 |
| Current Ratio (X) | 1.76 | 2.08 | 2.25 | 2.74 | 1.72 |
| Quick Ratio (X) | 1.18 | 1.44 | 1.52 | 1.75 | 1.10 |
| Inventory Turnover Ratio (X) | 4.09 | 2.93 | 2.29 | 1.82 | 1.81 |
| Dividend Payout Ratio (NP) (%) | 37.51 | 28.38 | 53.10 | 10.62 | 10.53 |
| Dividend Payout Ratio (CP) (%) | 26.71 | 22.65 | 36.20 | 8.99 | 9.03 |
| Earning Retention Ratio (%) | 62.49 | 71.62 | 46.90 | 89.38 | 89.47 |
| Cash Earning Retention Ratio (%) | 73.29 | 77.35 | 63.80 | 91.01 | 90.97 |
| Interest Coverage Ratio (X) | 8.23 | 10.36 | 9.02 | 19.15 | 15.99 |
| Interest Coverage Ratio (Post Tax) (X) | 5.13 | 6.93 | 5.48 | 12.93 | 10.87 |
| Enterprise Value (Cr.) | 967.40 | 1330.79 | 595.14 | 1372.72 | 511.32 |
| EV / Net Operating Revenue (X) | 1.54 | 2.17 | 1.08 | 2.87 | 1.04 |
| EV / EBITDA (X) | 12.58 | 14.95 | 10.85 | 14.01 | 5.13 |
| MarketCap / Net Operating Revenue (X) | 1.34 | 2.03 | 0.96 | 2.84 | 0.92 |
| Retention Ratios (%) | 62.48 | 71.61 | 46.89 | 89.37 | 89.46 |
| Price / BV (X) | 1.63 | 2.54 | 1.21 | 3.19 | 1.85 |
| Price / Net Operating Revenue (X) | 1.34 | 2.03 | 0.96 | 2.84 | 0.92 |
| EarningsYield | 0.04 | 0.04 | 0.05 | 0.04 | 0.13 |
After reviewing the key financial ratios for Kopran Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.21. This value is within the healthy range. It has decreased from 13.24 (Mar 24) to 11.21, marking a decrease of 2.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 130.39. It has increased from 127.48 (Mar 24) to 130.39, marking an increase of 2.91.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.92. This value is within the healthy range. It has decreased from 18.47 (Mar 24) to 15.92, marking a decrease of 2.55.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 15.79 (Mar 24) to 12.69, marking a decrease of 3.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.76. This value is within the healthy range. It has decreased from 14.01 (Mar 24) to 10.76, marking a decrease of 3.25.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
- For PBDIT Margin (%), as of Mar 25, the value is 12.21. This value is within the healthy range. It has decreased from 14.48 (Mar 24) to 12.21, marking a decrease of 2.27.
- For PBIT Margin (%), as of Mar 25, the value is 9.73. This value is below the healthy minimum of 10. It has decreased from 12.38 (Mar 24) to 9.73, marking a decrease of 2.65.
- For PBT Margin (%), as of Mar 25, the value is 8.25. This value is below the healthy minimum of 10. It has decreased from 10.99 (Mar 24) to 8.25, marking a decrease of 2.74.
- For Net Profit Margin (%), as of Mar 25, the value is 6.12. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.12. This value is below the healthy minimum of 8. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 15. It has decreased from 10.37 (Mar 24) to 7.43, marking a decrease of 2.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.04. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.04, marking a decrease of 3.47.
- For Return On Assets (%), as of Mar 25, the value is 4.56. This value is below the healthy minimum of 5. It has decreased from 6.85 (Mar 24) to 4.56, marking a decrease of 2.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.28. This value is within the healthy range. It has increased from 0.20 (Mar 24) to 0.28, marking an increase of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.88 (Mar 24) to 0.79, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.76, marking a decrease of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.18, marking a decrease of 0.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.09. This value is within the healthy range. It has increased from 2.93 (Mar 24) to 4.09, marking an increase of 1.16.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.51. This value is within the healthy range. It has increased from 28.38 (Mar 24) to 37.51, marking an increase of 9.13.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 26.71. This value is within the healthy range. It has increased from 22.65 (Mar 24) to 26.71, marking an increase of 4.06.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.49. This value is within the healthy range. It has decreased from 71.62 (Mar 24) to 62.49, marking a decrease of 9.13.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 73.29. This value exceeds the healthy maximum of 70. It has decreased from 77.35 (Mar 24) to 73.29, marking a decrease of 4.06.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.23. This value is within the healthy range. It has decreased from 10.36 (Mar 24) to 8.23, marking a decrease of 2.13.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.13. This value is within the healthy range. It has decreased from 6.93 (Mar 24) to 5.13, marking a decrease of 1.80.
- For Enterprise Value (Cr.), as of Mar 25, the value is 967.40. It has decreased from 1,330.79 (Mar 24) to 967.40, marking a decrease of 363.39.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 2.17 (Mar 24) to 1.54, marking a decrease of 0.63.
- For EV / EBITDA (X), as of Mar 25, the value is 12.58. This value is within the healthy range. It has decreased from 14.95 (Mar 24) to 12.58, marking a decrease of 2.37.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
- For Retention Ratios (%), as of Mar 25, the value is 62.48. This value is within the healthy range. It has decreased from 71.61 (Mar 24) to 62.48, marking a decrease of 9.13.
- For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 1.63, marking a decrease of 0.91.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kopran Ltd:
- Net Profit Margin: 6.12%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.04% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 7.43% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 40.9 (Industry average Stock P/E: 42.93)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.28
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.12%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Parijat House, 1076, Dr. E. Moses Road, Mumbai Maharashtra 400018 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Susheel G Somani | Chairman |
| Mr. Surendra Somani | Executive Vice Chairman |
| Mr. Adarsh Somani | Director |
| Mr. Varun Somani | Director |
| Dr. Siddhan Subramanian | Independent Director |
| Dr. Sunita Banerji | Independent Director |
| Mrs. Mamta Biyani | Independent Director |
| Mr. Narayan Atal | Independent Director |
FAQ
What is the intrinsic value of Kopran Ltd?
Kopran Ltd's intrinsic value (as of 08 February 2026) is ₹207.06 which is 47.90% higher the current market price of ₹140.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹676 Cr. market cap, FY2025-2026 high/low of ₹215/120, reserves of ₹453 Cr, and liabilities of ₹813 Cr.
What is the Market Cap of Kopran Ltd?
The Market Cap of Kopran Ltd is 676 Cr..
What is the current Stock Price of Kopran Ltd as on 08 February 2026?
The current stock price of Kopran Ltd as on 08 February 2026 is ₹140.
What is the High / Low of Kopran Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kopran Ltd stocks is ₹215/120.
What is the Stock P/E of Kopran Ltd?
The Stock P/E of Kopran Ltd is 40.9.
What is the Book Value of Kopran Ltd?
The Book Value of Kopran Ltd is 104.
What is the Dividend Yield of Kopran Ltd?
The Dividend Yield of Kopran Ltd is 2.14 %.
What is the ROCE of Kopran Ltd?
The ROCE of Kopran Ltd is 9.75 %.
What is the ROE of Kopran Ltd?
The ROE of Kopran Ltd is 7.64 %.
What is the Face Value of Kopran Ltd?
The Face Value of Kopran Ltd is 10.0.